Inspections, Human Medicines Pharmacovigilance and Committees Division, Pharmacovigilance and Epidemiology Department, European Medicines Agency (EMA), London, E14 5EU, UK.
Information Management Division, Business Data and Analytics Department, European Medicines Agency (EMA), London, E14 5EU, UK.
Drug Saf. 2017 Dec;40(12):1241-1248. doi: 10.1007/s40264-017-0569-3.
Medication errors recently became the focus of regulatory guidance in pharmacovigilance to support reporting, evaluation and prevention of medication errors.
This study aims to characterise spontaneously reported cases of medication errors in EudraVigilance over the period 2002-2015 before the release of EU good practice guidance.
Case reports were identified through the adverse reaction section where a Medical Dictionary for Regulatory Activities (MedDRA) term is reported and included in the Standardised MedDRA Query (SMQ) for medication errors. These case reports were further categorised by MedDRA terms, geographical region, patient age group and Anatomical Therapeutic Chemical classification system of suspect medicinal product(s).
A total of 147,824 case reports were retrieved, 41,355 of which were from the European Economic Area (EEA). Approximately 60% of these case reports were retrieved with the narrow SMQ. The absolute number of medication error case reports and the proportion to the total number of reports in EudraVigilance increased during the study period, with peaks seen around 2005 and 2012 for cases with EEA origin. Fifty-two percent of case reports in which age was provided occurred in adults, 30% in the elderly and 18% in children, with almost half of these in children aged 2 months to 2 years.
Case reports of medication errors in EudraVigilance steadily increased between 2005 and 2015, the reasons for which may be multifactorial, including increased awareness, changes to the MedDRA terminology and the 2012 EU pharmacovigilance legislation and associated guidance for stakeholders, or a generally increased risk for errors as more medications become available.
药物错误最近成为药物警戒监管指导的重点,以支持药物错误的报告、评估和预防。
本研究旨在描述 2002 年至 2015 年在欧盟良好实践指南发布之前,在 EudraVigilance 中自发报告的药物错误案例。
通过不良反应部分识别病例报告,其中报告了一个监管活动医学词典(MedDRA)术语,并包含在药物错误的标准化 MedDRA 查询(SMQ)中。这些病例报告进一步按照 MedDRA 术语、地理区域、患者年龄组和可疑药物产品的解剖治疗化学分类系统进行分类。
共检索到 147824 例病例报告,其中 41355 例来自欧洲经济区(EEA)。大约 60%的病例报告是通过狭义的 SMQ 检索到的。在研究期间,药物错误病例报告的绝对数量和占 EudraVigilance 总报告数量的比例增加,EEA 来源的病例报告在 2005 年和 2012 年出现峰值。提供年龄信息的病例报告中,52%发生在成年人中,30%发生在老年人中,18%发生在儿童中,其中近一半发生在 2 个月至 2 岁的儿童中。
EudraVigilance 中的药物错误病例报告在 2005 年至 2015 年期间稳步增加,原因可能是多方面的,包括意识的提高、MedDRA 术语的变化以及 2012 年欧盟药物警戒立法及其对利益相关者的相关指导,或者随着更多药物的出现,错误的风险普遍增加。